Shire Plc (SHP):企業の財務・戦略的SWOT分析

◆英語タイトル:Shire Plc (SHP) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C2901
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:68
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Shire Plc (SHP) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Shire Plc (Shire) is a biotechnology company that focuses on the research, development, manufacturing, marketing, distribution and sale of novel pharmaceuticals to serve patients with rare diseases and other highly specialized conditions. It provides products across various therapeutic areas including hematology, neuroscience, immunology, genetic disease, ophthalmic, gastrointestinal, endocrine, hereditary angioedema, cancer and other diseases. The company primarily sells its products through pharmaceutical wholesale distributors and large pharmacies, in both the US and Europe. The company operates along with its subsidiaries and representative offices in Europe, the Americas, Asia Pacific, South Africa and other countries. Shire is headquartered in Dublin, Ireland.

Shire Plc Key Recent Developments

Jul 31,2018: Shire Delivers Q2 2018 Product Sales Growth of 6% and Continued Regulatory and Pipeline Progress
Jul 25,2018: Shire announces Director declaration
Jul 17,2018: argenx receives milestone payment from strategic collaboration with Shire
May 30,2018: Symphogen Further Strengthens its Immuno-Oncology Pipeline by Advancing into Two Additional Clinical Trials
May 02,2018: CENTOGENE Highlights Solutions for Early Diagnosis of Rare Hereditary Disorders at the 2nd Annual Recent Advances in Rare Disease Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Shire Plc – Key Facts 6
Shire Plc – Key Employees 7
Shire Plc – Key Employee Biographies 8
Shire Plc – Major Products and Services 9
Shire Plc – History 11
Shire Plc – Company Statement 20
Shire Plc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Joint Venture 29
Section 2 – Company Analysis 30
Company Overview 30
Shire Plc – Business Description 31
Product Category: Genetic Disease 31
Overview 31
Performance 31
Product Category: Hematology 31
Overview 31
Performance 32
Product Category: Immunology 32
Overview 32
Performance 32
Product Category: Internal Medicine 33
Overview 33
Performance 33
Product Category: Neuroscience 33
Overview 33
Performance 33
Product Category: Oncology 34
Overview 34
Performance 34
Product Category: Ophthalmology 34
Overview 34
Performance 34
Product Category: Royalties and Other Revenues 34
Overview 34
Performance 34
Geographical Segment: Ireland 35
Performance 35
Geographical Segment: Rest of the World 35
Performance 35
Geographical Segment: The US 35
Performance 35
R&D Overview 35
Shire Plc – Corporate Strategy 36
Shire Plc – SWOT Analysis 37
SWOT Analysis – Overview 37
Shire Plc – Strengths 37
Shire Plc – Weaknesses 38
Shire Plc – Opportunities 39
Shire Plc – Threats 40
Shire Plc – Key Competitors 41
Section 3 – Company Financial Ratios 42
Financial Ratios – Capital Market Ratios 42
Financial Ratios – Annual Ratios 43
Performance Chart 46
Financial Performance 46
Financial Ratios – Interim Ratios 47
Financial Ratios – Ratio Charts 48
Section 4 – Company’s Lifesciences Financial Deals and Alliances 49
Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 49
Shire Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 50
Shire Plc, Recent Deals Summary 51
Section 5 – Company’s Recent Developments 52
Jul 31, 2018: Shire Delivers Q2 2018 Product Sales Growth of 6% and Continued Regulatory and Pipeline Progress 52
Jul 25, 2018: Shire announces Director declaration 54
Jul 17, 2018: argenx receives milestone payment from strategic collaboration with Shire 55
May 30, 2018: Symphogen Further Strengthens its Immuno-Oncology Pipeline by Advancing into Two Additional Clinical Trials 56
May 02, 2018: CENTOGENE Highlights Solutions for Early Diagnosis of Rare Hereditary Disorders at the 2nd Annual Recent Advances in Rare Disease Conference 57
Apr 26, 2018: Shire Delivers 7% Product Sales Growth and Robust Pipeline Progress in Q1 2018 58
Mar 22, 2018: Shire Commits to Long-Term Responsibility Goals in 2017 Annual Responsibility Review 60
Mar 13, 2018: Shire Applies to Cease to be a Reporting Issuer in Canada 61
Mar 05, 2018: Shire Launches MyPKFi For Advate In U.S 62
Feb 20, 2018: Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases 63
Section 6 – Appendix 64
Methodology 64
Ratio Definitions 64
About GlobalData 68
Contact Us 68
Disclaimer 68

List of Tables
Shire Plc, Key Facts 6
Shire Plc, Key Employees 7
Shire Plc, Key Employee Biographies 8
Shire Plc, Major Products and Services 9
Shire Plc, History 11
Shire Plc, Other Locations 22
Shire Plc, Subsidiaries 22
Shire Plc, Joint Venture 29
Shire Plc, Key Competitors 41
Shire Plc, Ratios based on current share price 42
Shire Plc, Annual Ratios 43
Shire Plc, Annual Ratios (Cont...1) 44
Shire Plc, Annual Ratios (Cont...2) 45
Shire Plc, Interim Ratios 47
Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 49
Shire Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 50
Shire Plc, Recent Deals Summary 51
Currency Codes 64
Capital Market Ratios 64
Equity Ratios 65
Profitability Ratios 65
Cost Ratios 66
Liquidity Ratios 66
Leverage Ratios 67
Efficiency Ratios 67

List of Figures
Shire Plc, Performance Chart (2013 - 2017) 46
Shire Plc, Ratio Charts 48
Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 49
Shire Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 50

★海外企業調査レポート[Shire Plc (SHP):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cleveland BioLabs Inc (CBLI)-医療機器分野:企業M&A・提携分析
    Summary Cleveland BioLabs Inc (Cleveland) is a biopharmaceutical company that develops and commercializes drugs to treat cancer, orphan indications and protect healthy tissues from radiation and chemotherapy. The company’s product includes entolimod, a recombinant protein which acts as an agonist of …
  • Molecular Partners AG (MOLN):製薬・医療:M&Aディール及び事業提携情報
    Summary Molecular Partners AG (Molecular Partners) is a clinical stage biopharmaceutical company that provides biological drugs. The company provides advanced pipeline products such as abicipar, a designed ankyrin repeat protein based anti-angiogenic drug developed for diabetic macular edema and wet …
  • Levi Strauss & Co (LEVI):企業の財務・戦略的SWOT分析
    Levi Strauss & Co (LEVI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Alcami Corp:企業の戦略的SWOT分析
    Alcami Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Thai Airways International Public Co Ltd:企業の戦略・SWOT・財務情報
    Thai Airways International Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Thai Airways International Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Epigenomics AG (ECX):製薬・医療:M&Aディール及び事業提携情報
    Summary Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi pro …
  • G Adventures Inc:企業の戦略・SWOT・財務情報
    G Adventures Inc - Strategy, SWOT and Corporate Finance Report Summary G Adventures Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Edge Therapeutics Inc (EDGE):企業の財務・戦略的SWOT分析
    Summary Edge Therapeutics Inc (Edge Therapeutics) is a clinical-stage biotechnology company that discovers, develops and commercializes hospital-based therapies. The company offers hospital based therapies capable of transforming treatment paradigms in the management of life-threatening, acute neuro …
  • Tractebel Engineering:企業の戦略的SWOT分析
    Tractebel Engineering - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Union Jack Oil plc (UJO):石油・ガス:M&Aディール及び事業提携情報
    Summary Union Jack Oil plc (Union Jack Oil), formerly Union Jack Oil Ltd is an onshore oil and gas company that offers exploration and development of hydrocarbon projects. The company develops its portfolio of oil and gas assets by acquiring interests in drill ready prospects. It holds license inter …
  • Secure Energy Services Inc (SES):石油・ガス:M&Aディール及び事業提携情報
    Summary Secure Energy Services Inc. (Secure Energy) is an energy services company. It provides specialized services to upstream oil and natural gas companies operating in the Western Canadian Sedimentary Basin (WCSB) and North Dakota. The company assists these companies with the handling, processing …
  • Hill-Rom Holdings Inc (HRC):企業の財務・戦略的SWOT分析
    Hill-Rom Holdings Inc (HRC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Koken Co Ltd:企業の戦略的SWOT分析
    Koken Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Trinity Industries, Inc (TRN):電力:M&Aディール及び事業提携情報
    Summary Trinity Industries, Inc. (Trinity) is a diversified industrial company. It produces and supplies railcars and railcar parts, inland barges, aggregates and highway products. It also manufactures tank containers, steel parts and structural wind towers. It also offers services such as railcar f …
  • United Cooperative Services, Inc.:企業の戦略的SWOT分析
    United Cooperative Services, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Laboratoire HRA Pharma SAS-製薬・医療分野:企業M&A・提携分析
    Summary Laboratoire HRA Pharma (HRA Pharma) is a healthcare products provider that offers women’s health and endocrinology products. The company offers a wide range of women’s health products which include emergency contraception, uterine fibroids, regular contraception and genital herp products amo …
  • Galp Energia SGPS SA (GALP)-エネルギー分野:企業M&A・提携分析
    Summary Galp Energia SGPS S.A. (Galp Energia) is an integrated oil and natural gas company. It explores for, develops and produces crude oil and natural gas; refines crude oil and markets refined petroleum products. The company also imports, transports and distributes natural gas. It conducts the na …
  • C.A. Curtze Co. Inc.
    C.A. Curtze Co. Inc. - Strategy, SWOT and Corporate Finance Report Summary C.A. Curtze Co. Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Israel Chemicals Ltd.:企業の戦略・SWOT・財務分析
    Israel Chemicals Ltd. - Strategy, SWOT and Corporate Finance Report Summary Israel Chemicals Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • ams AG (AMS):企業の財務・戦略的SWOT分析
    Summary ams AG (ams) involves in manufacturing and marketing of semiconductor products. The offers various company's which include ultra small ANC speaker driver, environmental sensors, spectral sensing, CMOS imaging sensors, DC-DC boost converters and CT and digital X-ray . It offers power manageme …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆